Abbott Vascular Devices Launches Perclose(R) ProGlide(TM) Next Generation Suture-Mediated Vessel Closure System

May 05, 2004, 01:00 ET from Abbott Laboratories

    ABBOTT PARK, Ill., May 5 /PRNewswire-FirstCall/ -- Abbott Vascular
 Devices, a division of Abbott Laboratories (NYSE:   ABT), today announced the
 launch of the next generation Perclose(R) suture-mediated vessel closure
 system, Perclose ProGlide(TM), featuring polypropylene monofilament suture.
 The device received approval from the U.S. Food and Drug Administration (FDA)
 during the first quarter of 2004. Perclose closure devices are designed to
 close femoral artery puncture sites following diagnostic or interventional
 procedures. The company will feature Perclose ProGlide with product
 demonstrations and additional information at the Cardiovascular
 Revascularization Therapy 2004 symposium being held this week in Washington,
     Perclose ProGlide is an important addition to Abbott Vascular Devices -- a
 leader in vessel closure technologies with one of the broadest portfolios of
 vessel closure products on the market. With monofilament suture, the ProGlide
 knot easily advances to the opening in the artery, allowing a single operator
 to rapidly deliver a pre-tied knot to close the access site in the femoral
 artery following a catheterization procedure.  This secure stitch provides
 rapid hemostasis, or the cessation of bleeding, and allows patients to recover
 comfortably by providing the ability to get out of bed in a shorter amount of
 time.  Monofilament suture is also a preferred suture for vascular surgeons
 due to its high-knotted tensile strength and minimized tissue reaction.
     "We are pleased to offer Perclose ProGlide with monofilament suture, which
 expands the Perclose product line to include the same suture material used by
 vascular surgeons," said Robert B. Hance, president, Abbott Vascular Devices,
 Abbott Laboratories.  "This new generation of our suture-mediated closure
 system underscores our responsiveness to the needs of clinicians and their
 patients.  We are working to provide the industry's best products for the
 interventionalist's toolkit."
     "The incorporation of monofilament suture into the ProGlide device
 enhances suture handling, making a great device even easier to use," said Mark
 Dorogy, M.D., an interventional cardiologist at Central Georgia Heart Center,
 Medical Center of Central Georgia, Macon, Ga.  "The security of the suture
 enables my patients to get out of bed sooner, increasing their satisfaction."
     Additional features on Perclose ProGlide include the QuickCut(TM)
 mechanism, which is built into the device to trim the suture after deployment,
 making it unnecessary to use additional sharps during the procedure.  The
 trimmer facilitates both suture trimming and knot advancement, eliminating a
 potentially time-consuming step in the vessel closure procedure for many
 operators.  ProGlide also features numbered procedure deployment steps that
 are printed on the device.
     In addition, the FDA approved new product labeling for Perclose ProGlide
 that states there are no reaccess/repuncture restrictions if previous
 arteriotomy repairs were achieved with a Perclose suture-mediated closure
 device. This product labeling for Abbott Vascular Devices' Perclose closure
 products allows physicians to perform repeat procedures using the same access
 site immediately -- offering increased flexibility to physicians.
     Abbott Vascular Devices has also begun offering a Continuing Education
 Unit (CEU) course for nurses and technicians.  The course, titled "Building a
 Pathway for Better Patient Outcomes," focuses on the importance of proper
 access site management in catheter-based procedures and is available as either
 a one- or four-credit course.  More information is available on this
 educational course by calling your Abbott Vascular Devices representative or
 1-800-222-6883, or by visiting .
     About Suture-Mediated Closure
     American Heart Association research indicates that more than 61 million
 Americans have cardiovascular disease, and nearly 3 million cardiac
 catheterizations are conducted in the United States each year.  During cardiac
 catheterization procedures, a long, thin tube (called a catheter) is threaded
 through a major artery in the leg up to the heart to diagnose or treat certain
 problems with that organ and its blood supply. Traditionally, doctors have
 used various methods of applying compression to close the opening to the
 artery, including direct pressure, sandbags or mechanical clamps. These
 approaches to vessel closure often result in significant patient discomfort
 and can require up to several hours to achieve hemostasis.
     Since the launch of the first Perclose system in 1994, suture-mediated
 closure technology has enabled physicians to more quickly close the accessed
 vessel and reduce the bleeding after cardiac catheterization, allowing
 patients to ambulate safely and improving patient comfort.  In addition, a
 prospective study indicated that use of this technology allows patients to go
 home sooner, requiring less nursing time for post-procedure monitoring, which
 may result in cost savings.  Abbott Laboratories acquired Perclose, a leader
 in vessel closure devices, in 1999.
     About Perclose ProGlide
     The Perclose ProGlide 6F Suture-Mediated Closure (SMC) System is indicated
 for the percutaneous delivery of suture for closing the common femoral artery
 access site of patients who have undergone diagnostic or interventional
 catheterization procedures using 5F to 8F sheaths.  The Perclose ProGlide SMC
 System should only be used by physicians (or other health care professionals
 authorized by or under the direction of such physicians) who have been trained
 in the use of the Perclose ProGlide SMC System, e.g., participation in the
 Perclose ProGlide SMC System training program or equivalent.
     About Abbott Vascular Devices
     Abbott Vascular Devices, a division of Abbott Laboratories headquartered
 in Redwood City, Calif., is a medical technology pioneer that combines its
 entrepreneurial spirit with Abbott's pharmaceutical heritage to deliver
 specialized treatment options that dramatically improve the care of people
 with vascular disease.  Abbott Vascular Devices brings the best of these
 backgrounds together to develop unique products that meet the specialized
 needs of vascular disease treatment through three main business units: Vessel
 Closure Technologies, Coronary Technologies and Endovascular Technologies.
     About Abbott Laboratories
     Abbott Laboratories is a global, broad-based health care company devoted
 to the discovery, development, manufacture and marketing of pharmaceuticals
 and medical products, including nutritionals, devices and diagnostics.  The
 company employs more than 55,000 people and markets its products in more than
 130 countries.
     Abbott's news releases and other information are available on the
 company's Web site at .

SOURCE Abbott Laboratories